Efficacy of NSAID Transdermal Patch for Postoperative Management in Total Knee Arthroplasty

<b>Background:</b> While topical NSAID patches are effective in non-surgical knee conditions, their efficacy following total knee arthroplasty (TKA) remains understudied. The intention behind this study was the comparison of pain and functional score between esflurbiprofen and placebo patches for postoperative pain control after TKA. <b>Methods:</b> A triple-blinded randomized controlled trial was conducted among patients aged 55-80 years with primary knee osteoarthritis. Patients who had an allergy to study medications, had chronic kidney disease, had diabetes, used steroids, were unsuitable for spinal and subsartorial block, or were unwilling to participate were excluded. All eligible participants were randomized and assigned to either esflurbiprofen 40 mg transdermal patch or placebo patch starting from postoperative day 3 to 16 blindly and followed up for 3 months. Outcome assessment was a visual analog scale (VAS), morphine use, minimum daily VAS, time to minimum VAS, knee osteoarthritis outcome score, joint replacement (KOOS, JR), knee circumference, flexion angle, and adverse events. <b>Results:</b> Seventy patients underwent primary TKA (<i>n</i> = 35 each group). The average age and body mass index were 67.5 ± 13.7 years and 26.8 ± 4.5 kg/m<sup>2</sup>. There was no statistically significant difference in baseline characteristics between the two groups. When compared with the placebo group, the esflurbiprofen group presented statistically significantly diminished VAS scores after day 7 and morphine use at day 3 (<i>p</i> < 0.001), as well as subsequently enhanced KOOS scores at 6 weeks and 3 months (<i>p</i> < 0.001). No statistically significant difference between groups was found in terms of knee circumference, flexion angle, or time to minimum VAS (<i>p</i> > 0.05 for all). One patient in the esflurbiprofen group (2.86%) reported a mild skin reaction. <b>Conclusions:</b> Esflurbiprofen patches significantly reduce postoperative pain and improve short-term function after TKA without major complications.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2025-11-15
DOI
https://doi.org/10.3390/jcm14228098
Primary Topic
Total Knee Arthroplasty Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy of NSAID Transdermal Patch for Postoperative Management in Total Knee Arthroplasty

Kulapat Chulsomlee, Paphon Sa-ngasoongsong, Chavarat Jarungvittayakon, Siwadol Wongsak et al.
Journal of Clinical Medicine
Total Knee Arthroplasty Outcomes
article

Efficacy of NSAID Transdermal Patch for Postoperative Management in Total Knee Arthroplasty

Kulapat Chulsomlee, Paphon Sa-ngasoongsong, Chavarat Jarungvittayakon, Siwadol Wongsak, Khanawan Tubsrinuan
article en

Abstract

<b>Background:</b> While topical NSAID patches are effective in non-surgical knee conditions, their efficacy following total knee arthroplasty (TKA) remains understudied. The intention behind this study was the comparison of pain and functional score between esflurbiprofen and placebo patches for postoperative pain control after TKA. <b>Methods:</b> A triple-blinded randomized controlled trial was conducted among patients aged 55-80 years with primary knee osteoarthritis. Patients who had an allergy to study medications, had chronic kidney disease, had diabetes, used steroids, were unsuitable for spinal and subsartorial block, or were unwilling to participate were excluded. All eligible participants were randomized and assigned to either esflurbiprofen 40 mg transdermal patch or placebo patch starting from postoperative day 3 to 16 blindly and followed up for 3 months. Outcome assessment was a visual analog scale (VAS), morphine use, minimum daily VAS, time to minimum VAS, knee osteoarthritis outcome score, joint replacement (KOOS, JR), knee circumference, flexion angle, and adverse events. <b>Results:</b> Seventy patients underwent primary TKA (<i>n</i> = 35 each group). The average age and body mass index were 67.5 ± 13.7 years and 26.8 ± 4.5 kg/m<sup>2</sup>. There was no statistically significant difference in baseline characteristics between the two groups. When compared with the placebo group, the esflurbiprofen group presented statistically significantly diminished VAS scores after day 7 and morphine use at day 3 (<i>p</i> < 0.001), as well as subsequently enhanced KOOS scores at 6 weeks and 3 months (<i>p</i> < 0.001). No statistically significant difference between groups was found in terms of knee circumference, flexion angle, or time to minimum VAS (<i>p</i> > 0.05 for all). One patient in the esflurbiprofen group (2.86%) reported a mild skin reaction. <b>Conclusions:</b> Esflurbiprofen patches significantly reduce postoperative pain and improve short-term function after TKA without major complications.

Journal of Clinical MedicineVol. 14(22)
Mahidol University (TH), Ramathibodi Hospital (TH)
Openalex Percentile: Top 46%
Total Knee Arthroplasty Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.